U.K.’s Ario Pharma Raises $3M Series A For Cough Therapy
This article was originally published in The Pink Sheet Daily
New spin-out Ario Pharma is targeting idiopathic cough and cough associated with COPD for Phase II studies of its TRPV1 ion channel antagonist, supported by $3 million in financing from VCs in the U.S. and Europe.
You may also be interested in...
Britain moves ahead with a drug-repurposing research program that brings together big pharma and academic researchers in novel collaborations.
The U.K. biotech aims to transform the biologics market with its first-in-class human antibody-fragment technology, with mild to moderate psoriasis the lead therapeutic target.
U.K. biotech SEEK launches infirst HEALTHCARE to focus on commercializing consumer products, while the firm’s pipeline continues developing. Former GlaxoSmithKline exec Manfred Scheske leads infirst as it prepares cough remedy and analgesic launches in multiple markets.